---
title: "AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306157216.md"
description: "AstraZeneca has renewed its master services agreement with Tempus AI, committing $200 million through 2031. The deal includes a minimum annual spend of $32 million and extends the partnership until December 2031, with an automatic one-year extension if targets are missed. William Blair maintains a Market Perform rating on AstraZeneca, citing valuation discounts despite strong customer retention evidence from this renewal."
datetime: "2026-11-19T17:18:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306157216.md)
  - [en](https://longbridge.com/en/news/306157216.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306157216.md)
generator: "portal-rs"
---

# AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples

**Tempus AI Inc.** (NYSE:TEM) and **AstraZeneca Plc.** (NASDAQ:AZN) on Monday amended their master services agreement, extending the partnership through Dec. 31, 2031, establishing a new five-year financial commitment period starting Jan. 1, 2027.

 **• Tempus AI stock is among today’s weakest performers. Why is TEM stock falling?**

## **AstraZeneca Commits $200 Million to Tempus AI Through 2031**

Under the amendment, AstraZeneca committed to spend $200 million on Tempus AI’s existing and future products and services during the renewal period, targeting $40 million annually.

According to an SEC filing, the agreement also includes a minimum annual spending commitment of $32 million.

If AstraZeneca’s cumulative spending falls short of $200 million by the end of 2031, the agreement will automatically extend by one year, through Dec. 31, 2032, to cover the shortfall.

AstraZeneca retains the right to terminate the agreement at any time. However, if it terminates before fulfilling its financial commitment, it will be required to pay Tempus AI the remaining shortfall.

 **Read Also: Tempus AI Says It Is Uniquely Positioned** 

## **Analyst Views Renewal as Evidence of Customer Retention**

**William Blair** views the renewal as the most direct evidence yet that Tempus’s data business can hold a customer once the data is built into a pharma partner’s R&D process.

Analyst **Matt Larew** wrote that **AstraZeneca** was the first enterprise-wide data relationship, and it uses the data across its portfolio for decisions ranging from target selection to trial design.

William Blair reiterates the Market Perform rating on AstraZeneca.

## **Valuation Discount and Market Perform Rating**

Larew wrote that shares trade at ~6x 2027 consensus sales, a discount to the peer average of around 10x and its own (limited) history as a public company.

This valuation discount comes despite the multitude of long-term shots on goal across the diagnostics and data businesses.

For multiple expansion to materialize, we expect investors will want to see additional positive proof points on recent M&A contributing to numbers and more clarity on the growth profile and durability of the data business.

In October, Tempus expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for completely resected stage IIB-IV melanoma and other cancer types.

Intismeran autogene is jointly developed by **Moderna Inc.** (NASDAQ:MRNA) and **Merck & Co. Inc**. (NYSE:MRK).

**TEM Price Action:** Tempus AI shares were down 3.83% to $61.19 at the time of publication on Thursday, according to Benzinga Pro data.

*Photo: Piotr Swat / Shutterstock*

 **Read Also: Russian Agent Reportedly Stalked Palantir Employees, Photographed Laptop Screens and Tracked One Worker for 30 Miles: DOJ Calls It 'State-Sponsored Operation to Target and Harass'** 

 **See More: Top Momentum Stocks**

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [TEMC.US](https://longbridge.com/en/quote/TEMC.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [PLTR.US](https://longbridge.com/en/quote/PLTR.US.md)

## Related News & Research

- [Tempus Ai - Co And Astrazeneca AB Enter Fifth Amendment To Master Services Agreement On Nov 16](https://longbridge.com/en/news/305980109.md)
- [Tempus AI secures $200 million five-year commitment from AstraZeneca](https://longbridge.com/en/news/305978953.md)
- [Tempus AI to Present Breast Cancer Treatment Prediction Study at 2026 SABCS](https://longbridge.com/en/news/306119134.md)
- [AstraZeneca's sonesitatug vedotin gets FDA priority review for advanced gastric cancers](https://longbridge.com/en/news/306076537.md)
- [AstraZeneca (AZN) Wins FDA Approval for IMFINZI Bladder Cancer Regimen](https://longbridge.com/en/news/305514953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**